Dianthus Therapeutics (NASDAQ:DNTH) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report sent to investors on Friday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $135.00 price objective on the stock.

A number of other research firms also recently issued reports on DNTH. Truist Financial lifted their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Citigroup began coverage on shares of Dianthus Therapeutics in a report on Friday, September 4th. They set a “buy” rating and a $156.00 price target on the stock. Finally, Wedbush upped their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $129.83.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $106.20 on Friday. The firm’s fifty day simple moving average is $106.46 and its two-hundred day simple moving average is $91.38. Dianthus Therapeutics has a 12 month low of $32.22 and a 12 month high of $117.88. The stock has a market capitalization of $5.81 billion, a P/E ratio of -25.59 and a beta of 1.24.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. As a group, research analysts predict that Dianthus Therapeutics will post -3.83 EPS for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 16,167 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $110.38, for a total value of $1,784,513.46. Following the completion of the sale, the senior vice president owned 3,833 shares of the company’s stock, valued at $423,086.54. This represents a 80.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Simrat Randhawa sold 23,124 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $425,640. This trade represents a 85.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 283,678 shares of company stock valued at $29,672,400 over the last quarter. Company insiders own 3.02% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. BlackRock Inc. bought a new stake in Dianthus Therapeutics in the second quarter valued at $401,990,000. California State Teachers Retirement System lifted its position in shares of Dianthus Therapeutics by 10,003.2% in the 2nd quarter. California State Teachers Retirement System now owns 4,100,301 shares of the company’s stock worth $399,697,000 after purchasing an additional 4,059,717 shares during the period. Wellington Management Group LLP boosted its stake in shares of Dianthus Therapeutics by 24.4% during the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock valued at $314,849,000 after purchasing an additional 634,099 shares in the last quarter. Vestal Point Capital LP increased its position in shares of Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after buying an additional 1,499,931 shares during the period. Finally, TCG Crossover Management LLC raised its stake in Dianthus Therapeutics by 11.7% in the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after buying an additional 175,000 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company’s lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.